Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Khare, M.
Right arrow Articles by David, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khare, M.
Right arrow Articles by David, C. S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 15, No. 4, pp. 535-546, April 2003
© 2003 Japanese Society for Immunology

HLA class II transgenic mice authenticate restriction of myelin oligodendrocyte glycoprotein-specific immune response implicated in multiple sclerosis pathogenesis

Meenakshi Khare1, Moses Rodriguez1,2 and Chella S. David1

Departments of 1 Immunology and 2 Neurology, Mayo Clinic, Rochester, MN 55905, USA

Correspondence to: M. Rodriguez; E-mail: rodriguez.moses{at}mayo.edu
Transmitting editor: G. Hammerling

Myelin oligodendrocyte glycoprotein (MOG) is a potential target antigen of the central nervous system (CNS), known to induce autoreactive T cell response and demyelinating anti-MOG antibodies in multiple sclerosis (MS) patients. Association of HLA class II genes with MS is well established. To better understand the role of HLA class II molecules in disease pathogenesis, we generated transgenic mice that express HLA-DR2, -DR3, -DR4, -DQB1*0601, -DQB1*0604 and -DQ8 without mouse class II (Aß0). We have for the first time characterized the T and B cell epitopes of human MOG restricted by different HLA class II molecules. Immunization with recombinant MOG (rMOG) generated a strong CD4+ T cell-mediated response in an HLA class II-restricted manner. Cytokine analysis revealed an increase in pro-inflammatory (IFN-{gamma}, IL-12 and IL-6) and anti-inflammatory (IL-10) cytokines. T cell autoreactivity to MOG was directed against peptides 1–20, 31–50, 61–80 and 91–110, of which three are also immunodominant epitopes for MOG in MS. A strong B cell response to MOG was observed in all transgenic mice, and major B cell epitopes recognized were located within amino acids 1–30, 51–80 and 101–120 of human MOG, which consists of two epitopes reported in MS. Transgenic mice used in this study recognized the immunodominant MOG epitopes similar to HLA class II-restricted human T cells, and would therefore be valuable in elucidating the roles of HLA class II genes and autoantigens in MS.

Keywords: autoimmunity, experimental autoimmune encephalomyelitis, HLA class II, multiple sclerosis, myelin oligodendrocyte glycoprotein, transgenic/knockout mice


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Virol.Home page
M. Rodriguez, L. Zoecklein, J. G. Kerkvliet, K. D. Pavelko, L. Papke, C. L. Howe, L. R. Pease, and C. David
Human HLA-DR Transgenes Protect Mice from Fatal Virus-Induced Encephalomyelitis and Chronic Demyelination
J. Virol., April 1, 2008; 82(7): 3369 - 3380.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Senger, F. Maurano, M. F. Mazzeo, M. Gaita, O. Fierro, C. S. David, R. Troncone, S. Auricchio, R. A. Siciliano, and M. Rossi
Identification of Immunodominant Epitopes of {alpha}-Gliadin in HLA-DQ8 Transgenic Mice following Oral Immunization
J. Immunol., December 15, 2005; 175(12): 8087 - 8095.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. D. Margot, M. L. Ford, and B. D. Evavold
Amelioration of Established Experimental Autoimmune Encephalomyelitis by an MHC Anchor-Substituted Variant of Proteolipid Protein 139-151
J. Immunol., March 15, 2005; 174(6): 3352 - 3358.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.